Lower GI 2017

First page Table of contents Next page Last page
L00 Introduction.pdf1
L01.1 Case 1_Gambacorta7
L01.2 RC_brussels_case2_SC78
L02 assessing metastatic disease_Brown97
L03 Standard RT_Rödel144
L04 ESTRO Rectal chemoradiation_Rob Glynne Jones179
L05_Surgical concepts after CRT234
L06 ANAL CANCER - prognostic factors_nigel scott287
L7_L8_GBrownTNM ESTRO 2316
L9 What information can be derived from ypTNM, TRG, CRM_N Scott431
L10 RT fractionation_R Glynne-Jones462
L11 Role of Brachytherapy in Rectal C_Haustermans526
L12 Dose constrains for organ at risk_Gambacorta559
L13 Planning_rectal ca_fiorino619
L14 IGRT_ART_fiorino657
L17_New chemo_Targeted_Rödel682
L18_RECTAL CANCER WAW after CRT_Cunningham711
L19 trials_Rob Glynne_Jones746
L21_Staging and restaging_GBrownSCC771
L22_What is considered standard of care for radiotherapy_Haustermans787
L23_ESTRO Rectal chemoradiation_R Glynne-Jones807
L24_Role of salvage surgery for non-responders _Cunnigham861
L25 Atlas and contouring guidelines for anal cancer RT_Haustermans890
L26a_anal canal_short_advanced case924
L26b_anal canal_short_early case928
L27_Planning_anal canal ca_fiorino931
L28 Anal Tox_MA Gambacorta951
L29 ANAL CANCER - prognostic factors_Nigel983
L30_Biomarker_Anal_cancer_CRodel1012
L31 Anal trials_Rob Glynne-Jones1043

Made with